Liu Yan, Huang Da, Li Beilin, Liu Wenjing, Sooranna Suren R, Pan Xingshou, Huang Zhaohe, Guo Jun
Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China.
Department of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi 533000, P.R. China.
Exp Ther Med. 2020 Nov;20(5):119. doi: 10.3892/etm.2020.9247. Epub 2020 Sep 21.
α1-antitrypsin (AAT) is a protein released as part of the anti-inflammatory response. It regulates the activity of serine proteinases and has a crucial role in the pathogenesis of acute coronary syndrome (ACS). The present study aimed to examine its role in patients with ACS. The plasma samples of 117 patients were collected at the Cardiology Department of the Affiliated Hospital of Youjiang Medical University (Baise, China). These included 46 cases of ACS (who met the diagnostic criteria for ACS and had ≥50% luminal stenosis of any coronary vessel), 35 cases of stable angina (SA; with ≥50% luminal stenosis of any coronary vessel but in a stable condition) and 36 normal healthy controls (subjects with no luminal stenosis in their coronary arteries). Plasma AAT protein concentrations were measured by ELISA and clinical data were collected. The plasma levels of AAT protein in patients with ACS were lower than those in controls and cases of SA (P<0.05), and the levels tended to decrease with the number of coronary artery lesions involved. There were no significant associations of the expression of plasma AAT protein and the number of diseased vessels in patients or the degree of stenosis. There was no correlation between the plasma protein levels of AAT and Gensini scores of patients with ACS. In conclusion, the plasma AAT protein levels in patients with ACS may contribute to the occurrence and development of coronary artery disease.
α1-抗胰蛋白酶（AAT）是作为抗炎反应的一部分而释放的一种蛋白质。它调节丝氨酸蛋白酶的活性，在急性冠状动脉综合征（ACS）的发病机制中起关键作用。本研究旨在探讨其在ACS患者中的作用。在右江民族医学院附属医院（中国百色）心内科收集了117例患者的血浆样本。其中包括46例ACS患者（符合ACS诊断标准且任何冠状动脉血管腔狭窄≥50%）、35例稳定型心绞痛（SA；任何冠状动脉血管腔狭窄≥50%但病情稳定）和36例正常健康对照者（冠状动脉无腔狭窄）。采用酶联免疫吸附测定法（ELISA）检测血浆AAT蛋白浓度并收集临床资料。ACS患者血浆AAT蛋白水平低于对照组和SA患者（P<0.05），且该水平倾向于随累及的冠状动脉病变数量而降低。血浆AAT蛋白表达与患者病变血管数量或狭窄程度之间无显著相关性。ACS患者血浆AAT蛋白水平与Gensini评分之间无相关性。总之，ACS患者血浆AAT蛋白水平可能与冠状动脉疾病的发生和发展有关。
